CGT Industry Upgrading Park Tour · Shanghai Station: Ready to Go!
Yeasen
Tool Enzyme Raw Materials and Diagnostic Product R&D, Manufacturer
BRC BIOTECHNOLOGY
Biosafety Testing Service Provider
Legend Capital
Early-stage venture capital and growth-stage private equity investment institutions
Saifu Pharmaceutical
Preclinical CRO Service Provider
Event Time:November 29, 2023 (Wednesday) 13:30
Event Venue:Lecture Hall, 1st Floor, ATLATL Innovation R&D Center, No. 1077 Zhangheng Road, Pudong New Area, Shanghai
Co-organizers:HIEA, Hangzhou Xingcheng Biotechnology Co., Ltd., YeasenYeasen, Saifu Pharmaceutical, BRC BIOTECHNOLOGY, Austar, Legend Capital, ATLATL Innovation Center
Organizer:VBMed
Stop 2: Shanghai Xingbei · Free Trade No.1
Event Duration:Thursday, November 30, 2023, 13:30
Activity VenuePoints:Conference Hall, 1st Floor, Building 6, Free Trade Zone No. 1 Life Science and Technology Industrial Park, No. 215 Fute South Road, Pudong New Area, Shanghai
Co-organizers:HIEA, Xingcheng Biotech, Yeasen, Saifu Pharmaceutical, BRC BIOTECHNOLOGY, Austar, Legend CapitalCapital
Organizer:VBMed
Supporting Organizations:Xingbei · Free Trade No.1, No.1 Entrepreneurs Club
After experiencing its first wave of development, China’s CGT industry has seen multiple CAR-T products filed for market approval, while several gene therapy products have entered Phase III clinical trials, continuously expanding into new disease areas and unlocking significant potential.
Meanwhile, the cell and gene therapy (CGT) industry continues to face numerous challenges, such as issues with product quality and batch-to-batch consistency, as well as constraints imposed by high costs and pricing. These factors have made the optimization and iteration of CGT products increasingly urgent. At the same time, the importance of Chemistry, Manufacturing, and Controls (CMC) cannot be overlooked. Designing superior products, reducing costs while improving efficiency, and developing effective therapeutics are the aspirations of every CGT company. Consequently, service providers across the industry chain and high-quality suppliers have become key drivers of industrial upgrading.
Based on this,CGT Industry Chain Service Providers Jointly Launch Park Tour Initiative, Leveraging Collective Strengths in Equipment, Raw Materials, Consumables, Process Design, and Advanced Analytical Methods to Support Innovative Enterprises in Developing High-Quality Therapeutics and Driving Industrial Upgrading of the CGT Sector.
High-net-worth attendees:Corporate founders and department heads or above attend the conference to learn from best practices.
Highly Practical Content:The invited guests will engage in in-depth discussions on topics including methodologies for cell and gene therapy, lessons learned from common pitfalls, service case studies, and insights into emerging trends.
Precise Matchmaking and Communication:Implement an audit system and extend targeted invitations to guests to ensure the quality of participating companies.
This “Shanghai Tour” serves as an inaugural exploratory initiative. Similar events will be held in other industrial parks in the future to promote the continuous upgrading and development of the CGT industry. We look forward to engaging in dialogue and fostering mutual progress with our industry peers, thereby helping the CGT sector go further!
Stop 1: Shanghai ATLATL Innovation Center
Co-organized by:HIEA, Hangzhou Xingcheng Biotechnology Co., Ltd., YeasenYeasen, Saifu Pharmaceutical, BRC BIOTECHNOLOGY, Austar, Legend Capital, ATLATL Innovation Center
■ 13:30–13:35 Host’s Opening Remarks + Introduction to the Ecosystem
Host | Event Expectations and Ecosystem Synergy
■ 13:35-13:40 Opening Remarks by Park Leadership
Zhangjiang Group
■ Keynote Speech
13：40-14：05
Legend Capital |My Perspective on Investment and Financing in the Cell and Gene Therapy Industry
14：05-14：30
Yeasen |The Secret to Scientifically Reducing Costs and Increasing Efficiency in Raw Materials for Cell and Gene Therapy Manufacturing
14：30-14：55
Xingcheng Biotechnology |Key Points of CMC in Cell and Gene Therapy
14：55-15：20
Saifu Pharmaceutical |Preclinical Research under the Dual-Track Integration of IIT and IND for Cell-Based Products
■ 15:20-15:30 Tea Break
■ Keynote Speech
15：30-15：55
BRC BIOTECHNOLOGY |Key Explorations to Facilitate the Industrial Upgrading of CGT
15：55-16：20
Austar |Providing Technology-Driven Pharmaceutical Engineering Solutions to Enhance Cell Therapy Process Efficiency
■ 16:20-17:00 Roundtable Discussion
Leveraging CMC Synergy to Help Innovative Companies Achieve Robust, Rapid, and Cost-Effective Progression from IIT/IND to BLA
■ 17:00-19:00 Dinner Reception
Stop 2: Shanghai Xingbei·Free Trade No.1
Co-organized by:HIEA, Xingcheng Biotechnology, Yeasen, Saifu Pharmaceutical, BRC BIOTECHNOLOGY, Austar, Legend CapitalCapital
Supporting Organizations: Xingbei · Free Trade No.1, No.1 Entrepreneurs Club
■ 13:30-13:35 Host's Opening Remarks + Introduction to the Ecosystem
Moderator | Event Expectations and Ecosystem Synergy
■ 13:35-13:40 Address by Park Leadership
Xingbei · Free Trade No.1
■ Keynote Speech
13：40-14：05
Legend Capital |My Perspectives on Investment and Financing in the Cell and Gene Therapy Industry
14：05-14：30
Yeasen |The Key to Scientifically Reducing Costs and Increasing Efficiency in Raw Materials for Cell and Gene Therapy Production
14：30-14：55
Xingcheng Biotech |Key Considerations for CMC in Cell and Gene Therapy
14：55-15：20
Saifu Pharmaceutical |Preclinical Research under the Dual-Track Integration of IIT and IND for Cell-Based Products
■ 15:20-15:30 Tea Break
■ Keynote Speech
15：30-15：55
BRC BIOTECHNOLOGY |Rationalization of Cell Therapy and Domestic Substitution in China
15：55-16：20
Austar |Delivering Technology-Driven Pharmaceutical Engineering Solutions to Enhance Cell Therapy Process Efficiency
■ 16:20-17:00 Roundtable Discussion
Leveraging CMC Synergy to Help Innovative Enterprises Achieve a Robust, Rapid, and Cost-Effective Transition from IIT/IND to BLA
■ 17:00-19:00 Dinner Networking
Through this series of events, participants will have the opportunity to engage with the latest R&D achievements and technological trends in the industry, expand their professional networks, gain insights into policies and regulations, broaden market channels, and enhance their competitiveness. Meanwhile, these initiatives will further facilitate the upgrading of the cell and gene therapy industry, contributing to human health and well-being.
We warmly welcome practitioners, researchers, investors, and other stakeholders in the cell and gene therapy (CGT) field to participate in this event, jointly exploring and promoting the future development of the CGT industry.
To ensure the quality of the event, a registration review system will be implemented.
Event Scale: 50 people/session
Event Collaboration: Ms. Fu 17851017836 (WeChat ID same as phone number)
Event Registration: Capillary 17782369627 (WeChat ID same as phone number)
